Mode
Text Size
Log in / Sign up
N/A N=95

Comparison of ARPE Prosthesis With the Literature

Arthritis

Enrolled (actual)
95
Serious AEs
17.9%
Results posted
Aug 2021
Primary outcome: Primary: Grip Strength — 17.8; 23.4; 24.7; 25 kg

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Zimmer Biomet
Primary completion
Oct 2020

Outcome Measures

OutcomeResultp-value
PRIMARY
Grip Strength
17.8; 23.4; 24.7; 25
PRIMARY
Key Pinch Strength
3.6; 5.8; 5.5; 5.9
PRIMARY
Tip Pinch Strength
2.7; 4.5; 4.6; 4.5
PRIMARY
VAS Pain
59.3; 11.1; 10.3; 7.1
SECONDARY
Motion - ROM Measurement - Radial Abduction
41.5; 53.1; 47.5; 43.8
SECONDARY
Motion - ROM Measurement - Palmar Abduction
43.2; 48.1; 47.8; 43.4
SECONDARY
EQ-5D - Health Status Score
0.4; 0.8; 0.8; 0.8
SECONDARY
EQ-5D - VAS Score
72.7; 74.1; 77.9; 76.2
SECONDARY
Number of Implants With Visible Radiolucency Line Around the Implanted Prosthesis
0; 0; 0
SECONDARY
Hand Function: DASH Questionnaire - Disability
41.7; 10.6; 10.2; 8.5
SECONDARY
Hand Function: DASH Questionnaire - Work
46.1; 11.1; 7.8; 5.8
SECONDARY
Hand Function: DASH Questionnaire - Sport
48.7; 6.7; 10.1; 2.2

Summary

This study is designed to document the objective and subjective measurements after trapeziometacarpal athroplasty with ARPE prosthesis and to compare those to literature values of outcome after trapeziectomy and trapeziectomy with ligament reconstruction and tendon interposition (LRTI), as published in a recent meta-analysis.

Eligibility Criteria

Inclusion/exclusion criteria are identical to those indications and contraindications stated in the package insert of the implant.

Inclusion Criteria

  • patients with trapezio-metacarpal arthritis Eaton Stage of trapezio-metacarpal arthritis: Stage II - IV
  • patients willing to return for follow up evaluation.

Exclusion Criteria

  • local or systemic infections
  • severe muscular, neurological or vascular deficiencies of the extremity involved
  • bone destruction or poor bone to affect implant stability
  • allergy to any of the components of the implant
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01904019). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search